Analyst Price Targets — IMVT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 6, 2026 12:55 pm | — | Wolfe Research | $50.00 | $24.97 | TheFly | Immunovant upgraded to Outperform at Wolfe on improving Graves' perception |
| December 18, 2025 1:29 pm | Yatin Suneja | Guggenheim | $41.00 | $26.27 | TheFly | Immunovant price target lowered to $41 from $44 at Guggenheim |
| October 14, 2025 10:12 am | — | Truist Financial | $16.00 | $17.35 | TheFly | Immunovant initiated with a Hold at Truist |
| September 10, 2024 6:40 am | Douglas Tsao | H.C. Wainwright | $51.00 | $30.20 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Immunovant (IMVT) |
| June 3, 2024 7:22 am | Leland Gershell | Oppenheimer | $46.00 | $25.39 | TheFly | Immunovant price target lowered to $46 from $50 at Oppenheimer |
| May 30, 2024 2:40 pm | Yatin Suneja | Guggenheim | $48.00 | $26.41 | StreetInsider | Immunovant (IMVT) PT Lowered to $48 at Guggenheim |
| May 30, 2024 7:41 am | Yasmeen Rahimi | Piper Sandler | $57.00 | $27.83 | StreetInsider | Piper Sandler Reiterates Overweight Rating on Immunovant (IMVT) |
| March 13, 2024 5:29 am | Corinne Johnson | Goldman Sachs | $50.00 | $31.82 | StreetInsider | Goldman Sachs Starts Immunovant (IMVT) at Buy |
| September 26, 2022 5:29 am | Colin Bristow | UBS | $5.00 | $4.88 | TheFly | Immunovant downgraded to Neutral from Buy at UBS |
Latest News for IMVT
NEW YORK, Feb. 17, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Immunovant, Inc. (NASDAQ:IMVT) on behalf of the company's shareholders. The investigation seeks to determine whether Immunovant, Inc.'s directors breached their fiduciary duties in connection with recent corporate actions.
Immunovant, Inc. (NASDAQ: IMVT - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Monday after the company announced better than expected quarterly earnings. The company traded as high as $27.92 and last traded at $27.1690, with a volume of 109492 shares. The stock had previously closed at $27.05. The company
Immunovant beats third-quarter estimates, raises $550M to fund IMVT-1402 through launch and advances multiple studies with key data ahead.
Immunovant, Inc. (IMVT) Q3 2026 Earnings Call Transcript
DURHAM, N.C., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported its financial results for the third quarter ended December 31, 2025.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IMVT.
U.S. House Trading
No House trades found for IMVT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.